347 related articles for article (PubMed ID: 15040586)
41. In vivo biological responses in the presence or absence of C3.
Sarma JV; Ward PA
Adv Exp Med Biol; 2007; 598():240-50. PubMed ID: 17892216
[No Abstract] [Full Text] [Related]
42. The complement anaphylatoxin C5a induces apoptosis in adrenomedullary cells during experimental sepsis.
Flierl MA; Rittirsch D; Chen AJ; Nadeau BA; Day DE; Sarma JV; Huber-Lang MS; Ward PA
PLoS One; 2008 Jul; 3(7):e2560. PubMed ID: 18648551
[TBL] [Abstract][Full Text] [Related]
43. Targeting Complement C5a Receptor 1 for the Treatment of Immunosuppression in Sepsis.
Sommerfeld O; Medyukhina A; Neugebauer S; Ghait M; Ulferts S; Lupp A; König R; Wetzker R; Schulz S; Figge MT; Bauer M; Press AT
Mol Ther; 2021 Jan; 29(1):338-346. PubMed ID: 32966769
[TBL] [Abstract][Full Text] [Related]
44. Effective suppression of C5a-induced proinflammatory response using anti-human C5a repebody.
Hwang DE; Choi JM; Yang CS; Lee JJ; Heu W; Jo EK; Kim HS
Biochem Biophys Res Commun; 2016 Sep; 477(4):1072-1077. PubMed ID: 27416759
[TBL] [Abstract][Full Text] [Related]
45. Role of complement C5a and histones in septic cardiomyopathy.
Fattahi F; Frydrych LM; Bian G; Kalbitz M; Herron TJ; Malan EA; Delano MJ; Ward PA
Mol Immunol; 2018 Oct; 102():32-41. PubMed ID: 29914696
[TBL] [Abstract][Full Text] [Related]
46. New insights into cellular mechanisms during sepsis.
Hoesel LM; Gao H; Ward PA
Immunol Res; 2006; 34(2):133-41. PubMed ID: 16760573
[TBL] [Abstract][Full Text] [Related]
47. Novel C5a regulators in inflammatory disease.
Mizuno M; Cole DS
Expert Opin Investig Drugs; 2005 Jul; 14(7):807-21. PubMed ID: 16022570
[TBL] [Abstract][Full Text] [Related]
48. Receptor residence time trumps drug-likeness and oral bioavailability in determining efficacy of complement C5a antagonists.
Seow V; Lim J; Cotterell AJ; Yau MK; Xu W; Lohman RJ; Kok WM; Stoermer MJ; Sweet MJ; Reid RC; Suen JY; Fairlie DP
Sci Rep; 2016 Apr; 6():24575. PubMed ID: 27094554
[TBL] [Abstract][Full Text] [Related]
49. Complement in sepsis-when science meets clinics.
Mollnes TE; Huber-Lang M
FEBS Lett; 2020 Aug; 594(16):2621-2632. PubMed ID: 32621378
[TBL] [Abstract][Full Text] [Related]
50. Therapeutic Potential of Targeting Complement C5a Receptors in Diabetic Kidney Disease.
Trambas IA; Coughlan MT; Tan SM
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240105
[TBL] [Abstract][Full Text] [Related]
51. Role of the complement in experimental sepsis.
Ward PA
J Leukoc Biol; 2008 Mar; 83(3):467-70. PubMed ID: 17875813
[TBL] [Abstract][Full Text] [Related]
52. Complement and sepsis-induced heart dysfunction.
Fattahi F; Ward PA
Mol Immunol; 2017 Apr; 84():57-64. PubMed ID: 27931779
[TBL] [Abstract][Full Text] [Related]
53. Never make assumptions: the complicated role of complement in urinary tract infections.
Thurman JM; Nemenoff RA
Kidney Int; 2016 Sep; 90(3):469-71. PubMed ID: 27521106
[TBL] [Abstract][Full Text] [Related]
54. Cutting edge: critical role for C5aRs in the development of septic lymphopenia in mice.
Grailer JJ; Fattahi F; Dick RS; Zetoune FS; Ward PA
J Immunol; 2015 Feb; 194(3):868-72. PubMed ID: 25539817
[TBL] [Abstract][Full Text] [Related]
55. [Involvement of the complement cascade in severe forms of COVID-19].
Chouaki Benmansour N; Carvelli J; Vivier É
Med Sci (Paris); 2021 Apr; 37(4):333-341. PubMed ID: 33835019
[TBL] [Abstract][Full Text] [Related]
56. Complement C5a in the sepsis syndrome--too much of a good thing?
Gerard C
N Engl J Med; 2003 Jan; 348(2):167-9. PubMed ID: 12519929
[No Abstract] [Full Text] [Related]
57. Inhibition of complement C5a prevents breakdown of the blood-brain barrier and pituitary dysfunction in experimental sepsis.
Flierl MA; Stahel PF; Rittirsch D; Huber-Lang M; Niederbichler AD; Hoesel LM; Touban BM; Morgan SJ; Smith WR; Ward PA; Ipaktchi K
Crit Care; 2009; 13(1):R12. PubMed ID: 19196477
[TBL] [Abstract][Full Text] [Related]
58. Complement anaphylatoxin C5a contributes to hemodialysis-associated thrombosis.
Kourtzelis I; Markiewski MM; Doumas M; Rafail S; Kambas K; Mitroulis I; Panagoutsos S; Passadakis P; Vargemezis V; Magotti P; Qu H; Mollnes TE; Ritis K; Lambris JD
Blood; 2010 Jul; 116(4):631-9. PubMed ID: 20424189
[TBL] [Abstract][Full Text] [Related]
59. Sepsis-associated delirium: the pro and con of C5a blockade.
Annane D
Crit Care; 2009; 13(2):135. PubMed ID: 19439043
[TBL] [Abstract][Full Text] [Related]
60. Hemofiltration in human sepsis: evidence for elimination of immunomodulatory substances.
Hoffmann JN; Faist E; Deppisch R; Hartl WH; Inthorn D
Contrib Nephrol; 1995; 116():76-9. PubMed ID: 8529385
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
